Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse

British Journal of Cancer

Volumn 93, Issue 11, 2005, Pages 1285-1294

  Domingo Domenech, J ^a   Mellado, B ^a   Ferrer, B ^a   Truan, D ^a   Codony Servat, J ^a   Sauleda, S ^b   Alcover, J ^a   Campo, E ^a   Gascon, P ^a   Rovira, A ^a   Ross, J S ^c,d   Fernandez P L ^a   Albanell, J ^a,e  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c ALBANY MEDICAL COLLEGE   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

Malignant transformation; NF kappa; B; Prostate cancer; PSA; Transcription factor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BASAL CELL; CANCER GRADING; CANCER RELAPSE; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STATISTICAL ANALYSIS;

ADENOCARCINOMA; AGED; CARRIER PROTEINS; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 27944434722     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602851     Document Type: Article

References (54)

1. Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 49-360
2. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: 6500-6510
3. Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C (2003) Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O- tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 63: 7106-7112
4. Andela VB, Gordon AH, Zotalis G, Rosier RN, Goater JJ, Lewis GD, Schwarz EM, Puzas JE, O'Keefe RJ (2003) NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop 415(Suppl): S75-S85
5. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y (2004) Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64: 5963-5972
6. Baldwin Jr AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683
7. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101: 10137-10142
8. Bostwick DG, Qian J (2004) High-grade prostatic intraepithelial neoplasia. Mod Pathol 17: 360-379
9. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20: 7342-7351
10. Chen CD, Sawyers CL (2002) NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22: 2862-2870
11. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM (2004) Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23: 1599-1607
12. Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116: 637-646
13. Flynn Jr V, Ramanitharan A, Moparty K, Davis R, Sikka S, Agrawal KC, Abdel-Mageed AB (2003) Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol 23: 317-323
14. Fradet V, Lessard L, Bégin LR, Karakiewicz P, Mes Masson A-M, Saad F (2004) Nuclear Factor-kB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10: 8460-8464
15. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115: 141-151
16. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 25-60
17. Gleason D (1992) Histologic grading of prostate cancer; a perspective. Hum Pathol 23: 273-279
18. Gunawardena K, Murray DK, Swope RE, Meikle AW (2002) Inhibition of nuclear factor kappaB induces apoptosis following treatment with tumor necrosis factor alpha and an antioxidant in human prostate cancer cells. Cancer Detect Prev 26: 229-237
19. Gupta S, Afaq F, Mukhtar H (2002) Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 21: 3727-3738
20. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF (2003) Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res 63: 1359-1364
21. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197
22. Ismail HA, Lessard L, Mes-Masson AM, Saad F (2004) Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 58: 308-313
23. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310
24. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26
25. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M (2003) Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 63: 107-110
26. Kim BY, Gaynor RB, Song K, Dritschilo A, Jung M (2002) Constitutive activation of NF-kappaB in Ki-ras-transformed prostate epithelial cells. Oncogene 21: 4490-4497
27. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F (2003) NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 91: 417-420
28. Li Y, Sarkar FH (2002) Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8: 2369-2377
29. Lu T, Burdelya LG, Swiatkowski SM, Boiko AD, Howe PH, Stark GR, Gudkov AV (2004) Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101: 7112-7117
30. Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin Jr AS, Whang YE (2002) PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 277: 11116-11125
31. Michalaki V, Syrigos K, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90: 2312-2316
32. Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ (2000) Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha 'super-repressor'. Clin Cancer Res 6: 1969-1977
33. Nair A, Venkatraman M, Maliekal TT, Nair B, Karunagaran D (2003) NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 22: 50-58
34. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706
35. Nakayama H, Ikebe T, Beppu M, Shirasuna K (2001) High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92: 3037-3044
36. Natoli G, Saccani S, Bisisio D, Marazzi I (2005) Interations of NF-κB with chromatin: the art of being at the right place at the right time. Nat Immunol 6: 439-445
37. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A (2001) Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93: 1739-1746
38. Ohori M, Wheeler T, Scardino P (1994) The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Cancer (Phila) 74: 104-114
39. Orlowski RZ, Baldwin Jr AS (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389
40. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18: 7389-7394
41. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X (2004) Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol 204: 569-577
42. Papandreou CN, Logothetis CJ (2004) Bortezomib as a potential treatment for prostate cancer. Cancer Res 64: 5036-5043
43. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG (2003) Transforming growth factor-betal activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22: 4314-4332
44. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597
45. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947
46. Ross JS, Jennings TA, Nazeer T, Sheehan CE, Fisher HA, Kauffman RA, Anwar S, Kallakury BV (2003) Prognostic factors in prostate cancer. Am J Clin Pathol 120(Suppl): S85-S100
47. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman Jr RP, Kaur P, Gray K, Stringer B (2004) Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 10: 2466-2472
48. Sanchez-Perez I, Benitah SA, Martinez-Gomariz M, Lacal JC, Perona R (2002) Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell 13: 2933-2945
49. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M (2001) Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7: 4136-4142
50. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB (2002) Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52: 183-200
51. Suh J, Rabson AB (2004) NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 91: 100-117
52. Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F (2003) Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 65: 37-45
53. Yu R, Mandlekar S, Ruben S, Ni JKong AN (2000) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 60: 2384-2389
54. Zerbini LF, Wang Y, Cho JY, Libermann TA (2003) Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215